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In postmenopausal women, some uterine leiomyosarcomas mimic a cystic 
degeneration of uterine myoma: two case reports and a literature review
U kobiet w okresie pomenopauzalnym mięsak gładkokomórkowy macicy może imitować 
zwyrodnienie torbielowate mięśniaka macicy – opis dwóch przypadków i przegląd literatury
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Uterine leiomyosarcoma is an uncommon malignancy accounting for approximately 1% of gynecologic oncology cases. Most 
uterine leiomyosarcomas occur in menopausal women and they are notorious for their aggressive character, early 
dissemination, and poor prognosis. It is difficult to accurately differentiate uterine leiomyosarcoma from leiomyomas, 
especially when leiomyomas undergo degenerative changes. We treated two menopausal women with a uterine mass showing 
cystic change. Clinical work-up included needle aspiration, sonography, computed tomography, and serum tumor markers 
to differentiate uterine leiomyosarcoma from leiomyoma. All results were negative for malignancy, but uterine leiomyosarcoma 
was ultimately diagnosed by pathological examination. Until an accurate preoperative diagnostic method is available, 
menopausal women diagnosed with a degenerating cystic uterine fibroid should be considered to have a malignancy 
intraoperatively in order to prevent tumor cells from intraperitoneal spreading.
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Mięsak gładkokomórkowy macicy to rzadki nowotwór złośliwy odpowiadający za około 1% przypadków nowotworów 
narządów rodnych. Nowotwór ten występuje głównie u kobiet w okresie pomenopauzalnym i jest znany z agresywnego 
przebiegu, wczesnego rozsiewu oraz złego rokowania. Przeprowadzenie dokładnej diagnostyki różnicującej mięsaka 
gładkokomórkowego i mięśniaków jest trudne, zwłaszcza w przypadku zmian degeneracyjnych tych drugich. W pracy 
przedstawiono przypadki dwóch kobiet w okresie pomenopauzalnym, u których w macicy stwierdzono obecność masy 
wykazującej zmianę torbielowatą. W  ramach diagnostyki klinicznej wykonano biopsję aspiracyjną, badanie 
ultrasonograficzne, tomografię komputerową oraz oznaczono stężenia markerów nowotworowych w surowicy krwi w celu 
zróżnicowania mięsaka gładkokomórkowego i mięśniaka. Chociaż wszystkie badania dały wynik ujemny dla nowotworu 
złośliwego, badanie histopatologiczne potwierdziło rozpoznanie mięsaka gładkokomórkowego macicy. Dopóki nie będzie 
dostępna dokładna metoda diagnozowania przedoperacyjnego, w  przypadku kobiet w  okresie pomenopauzalnym 
z rozpoznaniem zwyrodnienia torbielowatego mięśniaka macicy należy śródoperacyjne założyć obecność nowotworu 
złośliwego w celu uniknięcia dootrzewnowego rozsiewu komórek nowotworowych.
Słowa kluczowe: zwyrodnienie torbielowate mięśniaka macicy, mięsak gładkokomórkowy macicy, nowotwory złośliwe 
macicy
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Gynecological examination revealed a uterus that was sim-
ilar in size to that of a 10 weeks pregnant woman and a pal-
pable mass. Transvaginal sonography showed three masses 
in the uterus. One mass measured 6 cm, and was irregu-
lar in shape with cystic and solid components as well as 
calcifications. The other two masses measured 5 cm and 
3 cm, were encapsulated by a continuous membrane and 
filled with fluid contents. Also the thickness of the uterine 
endometrium was as thin as 0.4 cm. The results of labora-
tory test were within normal limits: CA-125 7.3 U/mL (nor-
mal range 0–35), CA 19-9 ≤3.0 U/mL (normal range 0–37). 
Abdominal and pelvic computed tomography (CT) showed 
that the central portion of the mass was cystic with calcifica-
tions, and the mass did not invade adjacent tissues; multiple 
uterine leiomyomas with secondary degeneration, intramu-
ral type (Fig. 1A), were diagnosed. Considering the masses 
to be benign, we performed total abdominal hysterectomy 
and bilateral salphingo-oophorectomy.
On gross examination, a 6 cm intramural mass was present, 
consisting of gray white soft tissue with a central irregular 
cystic lesion filled with clear serous fluid, and with a focally 
ill-defined margin (Fig. 1B). On microscopic examina-
tion, the largest solid region showed coagulative tumor cell 
necrosis, low mitotic count [<10/high-power field (HPF)], 
and diffuse moderate cellular atypia (Fig. 1C, 1D). This was 
consistent with uterine LMS and staged as IB according to 
the International Federation of Gynecology and Obstet-
rics (FIGO) classification. Two other histologic diagnoses 
revealed intramural and subserosal leiomyomas.
INTRODUCTION
Uterine leiomyosarcoma (LMS) is a  rare tumor, accounting for approximately 1% of uterine malig-nancies(1,2). Despite its rarity, LMS has the worst 
prognosis of all uterine malignancies and a high recur-
rence rate of 53%(1). Some study reported that the impact 
of primarily surgical manipulation in LMS on prognosis is 
important(3). However, LMS is usually diagnosed postop-
eratively because its symptoms and signs resemble those 
of leiomyoma, and there are no accurate tools available for 
preoperative diagnosis(1). We report two cases of LMS in 
which the diagnosis of leiomyoma was made before surgery. 
Both cases were initially presumed to be cystic degenerat-
ing leiomyomas, and the patients underwent total hysterec-
tomy; the final diagnosis of LMS was made by histopatho-
logical examination.
CASE REPORT
Case 1
A  52-year-old Korean woman (gravida 2, para 2) was 
admitted to our hospital with the chief complaint of vag-
inal spotting, which had persisted for 1 month. She had 
taken conjugated estrogens and bazedoxifene for 2 years 
since menopausal symptoms and had a history of myo-
mectomy 20 years before. Two years ago, the patient was 
diagnosed with 3 cm, 4 cm, and 5 cm uterine myomas. 
Fig. 1  A. Abdominal and pelvic CT suggested a diagnosis of multiple uterine leiomyomas (6 cm, 5 cm, 3 cm) with secondary degeneration,  
intramural type. B. On gross examination, uterine mass was 6 cm, intramural, with a central irregular cystic lesion and clear serous 
fluid. C. On microscopic examination, coagulative tumor cell necrosis was present (hematoxylin and eosin, ×400). D. On microscopic 
examination, low mitotic count (<10/high power field) and diffuse moderate cellular atypia was present (hematoxylin and eosin, ×400)
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Positron-emitting tomography-CT was performed postop-
eratively to evaluate for distant metastasis; there was no evi-
dence of malignancy. The patient reported for a follow-up 
involving abdominal, pelvic and chest CT every 3 months. 
The patient showed no clinical evidence of tumor recur-
rence or metastasis 10 months after surgery.
Case 2
A 52-year-old Korean, menopausal woman (gravida 2, 
para 2) visited her physician due to a 2-month history of 
lower abdominal discomfort and a palpable mass. She never 
received hormone therapy and had no other gynecologic 
history. Transvaginal sonography showed an abnormal cys-
tic uterus mass, and the patient was transferred to our hos-
pital for further evaluation. On gynecologic examination, 
a soft and firm mass was palpable, which corresponded to 
about 10 weeks pregnant uterus. Serum hemoglobin was 
12 g/dL; other laboratory parameters, including tumor 
markers (CA-125, CA 19-9) were non-specific. Transvag-
inal sonography revealed a well-circumscribed, approx-
imately 10 cm uterine mass with cystic and solid com-
ponents (Fig. 2A). We aspirated the cystic lesion under 
ultrasonographic guidance and cytologic results were neg-
ative for malignancy. Based on the presumed diagnosis of 
a degenerating cystic uterine leiomyoma, we performed 
total laparoscopic hysterectomy. Based on an intraoper-
ative frozen pathology assessment, it was difficult to dis-
tinguish between malignant and benign lesion because the 
differentiation of the cells was very low and the shape of 
the cells was broken; therefore bilateral salphingo-oopho-
rectomy was performed. During operation, no cancer cell 
spilled into the operative field.
Grossly, the uterus showed a 9 × 7 cm intramural mass with 
a soft and yellowish gray fish-flesh-like cut surface (Fig. 2B). 
On pathological examination, the uterine smooth mus-
cle showed coagulative tumor cell necrosis, a high mitotic 
index (≥10/HPF), and diffuse mild cellular atypia (Fig. 2C, 
2D). These findings were consistent with the diagnosis of 
uterine LMS.
Postoperatively, abdominal, pelvic and chest CT was per-
formed to rule out metastasis. No significant findings were 
revealed and the patient was ultimately diagnosed with 
uterine LMS, staged as IB according to the FIGO classifica-
tion. A follow-up abdominal, pelvic and chest CT was per-
formed after 3 months. There was no clinical evidence of 
tumor recurrence at 1 year after surgery.
DISCUSSION
Uterine sarcomas are rare tumors that account for approx-
imately 3% of all uterine malignancies(4). The most com-
mon type of uterine sarcoma is LMS (63%), followed by 
low/high grade endometrial stroma sarcoma (21%) and 
undifferentiated uterine sarcoma(4). Most uterine sarco-
mas occur in women over 40 years of age who usually pres-
ent with abnormal vaginal bleeding, a palpable pelvic mass, 
and pelvic pain(1). In menopausal women who are not on 
Fig. 2  A. Transvaginal sonography revealed a well-circumscribed, approximately 10 cm uterine mass with cystic and solid components. 
B. Grossly, the uterus showed a 9 × 7 cm intramural mass with a soft and yellowish gray fish-flesh-like cut surface. C–D. The uterine 
smooth muscle showed coagulative tumor cell necrosis, a high mitotic index (≥10/HPF), and diffuse mild cellular atypia (hematoxylin 
and eosin, ×400)
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hormonal replacement therapy and present with a rapid 
growth of a leiomyoma, malignancy should be suspected(1). 
It is difficult to accurately differentiate LMS from leiomy-
omas because both tumors develop from uterine smooth 
muscle and the symptoms and signs are similar. The inci-
dence of LMS found in women operated on for presumed 
uterine leiomyoma is approximately 0.5%(5). 
Unlike uterine leiomyoma, LMS are characterized by 
aggressive nature, early dissemination, and poor prognosis. 
Importantly, the treatment methods differ. Minimally 
invasive procedures can now be used in leiomyoma treat-
ment, while LMS is treated with total abdominal hysterec-
tomy without morcellation to prevent tumor cell spread-
ing throughout the pelvic cavity(1,6). It was reported that 
the recurrence rate of the uterine sarcoma is increased 
three times or more when using the morcellation(7). Also, 
patients undergoing intact removal of the uterus had signif-
icantly improved survival rates and decreased recurrence 
rates(8). Thus accurate diagnosis and proper treatment are 
important. Many studies distinguishing LMS from leio-
myoma preoperatively using radiological criteria, tumor 
markers, and cytology, as well as other factors have been 
reported. Exacoustos et al. reported that ultrasound find-
ings, including a single and large diameter lesion greater 
than 8 cm, marked peripheral and central vascularity as 
well as cystic degeneration, were significantly associated 
with LMS(9). However, these features were not observed 
in our two patients. Cho et al. reported that preoperative 
neutrophil-to-lymphocyte ratio (>2.1), large tumor size 
(>8 cm), and lower body mass index (≤20) could be use-
ful for the discrimination of LMS from leiomyoma(10). Goto 
et al. studied the relationship between magnetic resonance 
imaging-based and pathologic diagnosis in 130 patients 
with myoma and 10 patients with LMS. The  results 
showed 3% false positive, 0% false negative, 100% sensitiv-
ity, 96.9% specificity, and 71.4% positive predictive value, 
100% negative predictive value(12). Dynamic magnetic res-
onance imaging enhanced with Gd-DTPA combined with 
serum determination of lactate dehydrogenase (LDH) and 
LDH3 seems to be useful in the preoperative differential 
diagnosis of uterine LMS from degenerated leiomyoma(12). 
Transcervical needle biopsy using histopathologic scor-
ing (mitotic index, cytologic atypia, coagulative tumor cell 
necrosis, variant, vascular extension, marginal infiltration) 
is a reliable diagnostic tool(12,13). However, this test is lim-
ited because there is a restriction that the tumor should be 
involving or encroaching on the endometrium(13). So the 
roles of these modalities in the preoperative prediction of 
LMS remain unclear, and there is no accurate diagnostic 
tool available.
In our cases, in the course of treating menopausal women 
with a uterine mass showing cystic change, we performed 
needle aspiration, sonography, CT, and serum tumor 
markers to differentiate uterine LMS from leiomyoma. 
All results were negative for malignancy, so we preopera-
tively presumed a diagnosis of benign uterine leiomyoma. 
However, LMS was diagnosed by final pathological exam-
ination.
In conclusion, uterine LMS is very difficult to distinguish 
from a degenerating cystic uterine leiomyoma, especially 
in the menopausal state. Until an accurate preopera-
tive diagnostic modality becomes available, menopausal 
women with a cystic uterus mass diagnosed as uterine leio-
myoma should be treated surgically as if they had a malig-
nant diagnosis, in order to prevent tumor cells from 
spreading intraperitoneally.
Conflict of interest
The authors do not report any financial or personal connections with 
other persons or organizations, which might negatively affect the content 
of this publication and/or claim authorship rights to this publication.
References
1. D’Angelo E, Prat J: Uterine sarcomas: a review. Gynecol Oncol 
2010; 116: 131–139.
2. Nam JH, Park JY: Update on treatment of uterine sarcoma. Curr 
Opin Obstet Gynecol 2010; 22: 36–42.
3. Perri T, Korach J, Sadetzki S et al.: Uterine leiomyosarcoma: does 
the primary surgical procedure matter? Int J Gynecol Cancer 
2009; 19: 257–260.
4. Koh W, Greer BE, Abu-Rustum NR et al.: Uterine sarcoma, ver-
sion 1.2016: featured updates to the NCCN Guidelines. J Natl 
Compr Canc Netw 2015; 13: 1321–1331.
5. Harry VN, Narayansingh GV, Parkin DE: Uterine leiomyosarco-
mas: a  review of the diagnostic and therapeutic pitfalls. 
The Obstetrician & Gynaecologist 2007; 9: 88–94.
6. Pritts EA, Parker WH, Brown J et al.: Outcome of occult uterine 
leiomyosarcoma after surgery for presumed uterine fibroids: 
a systematic review. J Minim Invasive Gynecol 2015; 22: 26–33.
7. George S, Barysauskas C, Serrano C et al.: Retrospective cohort 
study evaluating the impact of intraperitoneal morcellation on 
outcomes of localized uterine leiomyosarcoma. Cancer 2014; 
120: 3154–3158.
8. Raine-Bennett T, Tucker LY, Zaritsky E et al.: Occult uterine sar-
coma and leiomyosarcoma: incidence of and survival associated 
with morcellation. Obstet Gynecol 2016; 127: 29–39.
9. Exacoustos C, Romanini ME, Amadio A et al.: Can gray-scale and 
color doppler sonography differentiate between uterine leiomyo-
sarcoma and leiomyoma? J Clin Ultrasound 2007; 35: 449–457.
10. Cho HY, Kim K, Kim YB et al.: Differential diagnosis between 
uterine sarcoma and leiomyoma using preoperative clinical char-
acteristics. J Obstet Gynaecol Res 2016; 42: 313–318.
11. Kawamura N, Ichimura T, Ito F et al.: Transcervical needle biop-
sy for the differential diagnosis between uterine sarcoma and 
leiomyoma. Cancer 2002; 94: 1713–1720.
12. Goto A, Takeuchi S, Sugimura K et al.: Usefulness of Gd-DTPA 
contrast-enhanced dynamic MRI and serum determination of 
LDH and its isozymes in the differential diagnosis of leiomyosar-
coma from degenerated leiomyoma of the uterus. Int J Gynecol 
Cancer 2002; 12: 354–361.
13. Sato K, Yuasa N, Fujita M et al.: Clinical application of diffusion-
weighted imaging for preoperative differentiation between uter-
ine leiomyoma and leiomyosarcoma. Am J Obstet Gynecol 2014; 
210: 368.e1–368.e8.
